Abstract
To confirm the efficacy of recombinant urate oxidase (rasburicase) and to establish its safety profile, we reviewed the data on 173 children and 72 adults with malignancy who were treated with this new uricolytic agent in a compassionate-use trial. Rasburicase (0.20 mg/kg) was administered intravenously daily for 1 to 7 days and could be given every 12 h for the initial 72 h. Subsequent courses were allowed at a later date. Rasburicase produced a dramatic decrease in uric acid concentrations in all patients whether they received it for prophylaxis (n = 79) or treatment (n = 166) (P < 0.001 in all comparisons between the levels at diagnosis and those after treatment). The median post-treatment levels were 0.5 to 0.7 mg/dl. Repeated administrations were also effective in all 11 evaluable patients. Four children and five adults had mild adverse reactions that were drug related or of unknown etiology. In two of the children, the adverse events occurred during the second course. Rasburicase is highly effective and safe in the prophylaxis or treatment of malignancy- or chemotherapy-associated hyperuricemia in children and adults.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Silverman P, Distelhorst CW . Metabolic emergencies in clinical oncology Semin Oncol 1989 16: 504–515
Jones DP, Mahmoud H, Chesney RW . Tumor lysis syndrome: pathogenesis and management Pediat Nephrol 1995 9: 206–212
Krakoff IH, Meyer RL . Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor JAMA 1965 193: 89–94
DeContiRC, Calabresi P . Use of allopurinol for the prevention and control of hyperuricemia in patients with neoplastic disease N Engl J Med 1966 274: 481–486
Hande KR . Allopurinol In: Chabner BA, Collins JM (eds) Cancer Chemotherapy: Principles and Practice Lippincott: Philadelphia 1990 pp 1144–1146
Greene ML, Fujimoto, WY, Seegmiller JE . Urinary xanthine stones – a rare complication of allopurinol therapy N Engl J Med 1969 280: 426–427
Band PR, Silverberg DS, Henderson, JF, Ulan RA, Wensel RH, Banerjee TK, Little AS . Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol N Engl J Med 1970 283: 354–357
Pui C-H, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, Ribeiro RC, Sandlund JT, Rivera GK, Evans WE, Mahmoud HH . Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies Leukemia 1997 11: 1813–1816
Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH . Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma J Clin Oncol 2001 19: 697–704
Lascombes F, Sommelet D, Gebhard F, Leverger G, Schaison G, Pinkerton R, Bosly A, Patte C, Boos J, Smedmyr B, Lederlin P, Stryckmans P . High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS) Blood 1998 92: (Suppl. 1) 237b
Goldman S, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS . A randomized comparison between rasburicase and allopurinol in children with lymphoma and leukemia at high risk of tumor lysis Blood 2001 97: 2998–3003
Choukair MK . Blood chemistries/body fluids In: Siberry GK, Iannone R (eds) The Harriet Lane Handbook: A Manual for Pediatric House Officers edn 15 Mosby-Year Book Inc: St Louis 1996 pp 119–130
Acknowledgements
This work was supported in part by grant CA-21765 from the National Cancer Institute, a grant from Sanofi-Synthelabo, a Center of Excellence grant from the State of Tennessee and American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pui, CH., Jeha, S., Irwin, D. et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15, 1505–1509 (2001). https://doi.org/10.1038/sj.leu.2402235
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402235
Keywords
This article is cited by
-
Uricase Modified Au/Ni/PANI Microrockets to Reduce Uric Acid Level
Catalysis Letters (2023)
-
Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study
Drugs in R&D (2023)
-
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
BioDrugs (2022)
-
Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose
3 Biotech (2017)
-
Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience
Indian Journal of Hematology and Blood Transfusion (2016)